Peptide Research

AOD-9604 is a modified fragment of human growth hormone (hGH) spanning amino acids 176-191, with an added tyrosine at the N-terminus to enhance stability. It was developed to isolate the lipolytic (fat-burning) activity of growth hormone from its growth-promoting and diabetogenic effects. The peptide stimulates lipolysis and inhibits lipogenesis through a mechanism distinct from the GH receptor, and notably does not induce IGF-1 production or affect blood glucose homeostasis.

The mechanism appears to involve activation of beta-3 adrenergic receptor-related pathways in adipose tissue. Research by Ng and colleagues demonstrated that AOD-9604 mimics the way natural growth hormone regulates fat metabolism — it stimulates the breakdown of stored triglycerides in adipocytes while simultaneously blocking the formation of new fat. Importantly, studies have confirmed it does not compete with hGH for receptor binding, suggesting it acts through an independent signaling pathway.

More recent research has explored AOD-9604's effects on cartilage. Studies have shown it may promote proteoglycan and collagen synthesis in chondrocytes, opening potential applications in osteoarthritis research beyond its original anti-obesity focus.

BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in human gastric juice. Its mechanisms of action are multifaceted and have been studied extensively in over 100 animal studies. A central aspect of its activity involves upregulation of growth factor expression, including VEGF (vascular endothelial growth factor), EGF (epidermal growth factor), and their receptors. This pro-angiogenic activity helps explain its remarkable wound-healing and tissue-repair properties observed across multiple tissue types.

BPC-157 also interacts with the nitric oxide (NO) system in a complex, context-dependent manner. It can rescue NO production when it is pathologically inhibited and can attenuate excessive NO when it is overproduced, suggesting a modulatory rather than unidirectional effect. Research by Sikiric et al. has demonstrated that BPC-157 interacts with the dopaminergic system and may counteract both the acute and chronic effects of dopaminergic agents, pointing to direct CNS activity.

At the gastrointestinal level, BPC-157 maintains mucosal integrity by promoting granulation tissue formation and angiogenesis within lesion sites. It has shown cytoprotective effects against NSAID-induced gastric damage, ethanol-induced lesions, and stress ulcers in numerous rodent models. The peptide appears to modulate the FAK-paxillin pathway, which is critical for cell migration and adhesion during wound repair.

Epitalon is a synthetic tetrapeptide based on the naturally occurring peptide epithalamin, which is extracted from the pineal gland. Developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, epitalon is the most extensively studied of the Khavinson peptide bioregulators. Its primary mechanism of action involves activation of telomerase, the enzyme responsible for maintaining telomere length at chromosome ends.

Telomeres shorten with each cell division, and this progressive shortening is considered a key hallmark of cellular aging. When telomeres become critically short, cells enter senescence or undergo apoptosis. Khavinson and colleagues demonstrated that epitalon can activate telomerase in human somatic cells, leading to elongation of telomeres and extension of cellular lifespan beyond the Hayflick limit. This was shown in human fetal fibroblast cultures where epitalon-treated cells underwent significantly more population doublings than controls.

Epitalon also influences melatonin production. As a pineal bioregulator, it has been shown to restore the nocturnal melatonin peak in aged primates, which normally declines with age. This melatonin-related activity provides a secondary mechanism through which epitalon may affect aging processes, given melatonin's roles as an antioxidant and circadian regulator.

GHK-Cu is a naturally occurring copper-binding tripeptide first identified in human plasma by Loren Pickart in 1973. It is found in blood, saliva, and urine, with plasma levels declining from about 200 ng/mL at age 20 to 80 ng/mL by age 60. The copper ion is essential for its biological activity, as it enables the peptide to serve as a bioavailable copper delivery system.

GHK-Cu exerts its biological effects through multiple well-characterized mechanisms. It powerfully stimulates collagen synthesis (types I and III), decorin, and glycosaminoglycan production in dermal fibroblasts. Simultaneously, it upregulates matrix metalloproteinases (MMPs) and their inhibitors (TIMPs), enabling coordinated tissue remodeling rather than simple collagen deposition. This remodeling capacity is key to its wound-healing effects — GHK-Cu promotes organized tissue repair rather than scar formation.

Beyond structural matrix effects, GHK-Cu has potent antioxidant activity via SOD and glutathione pathway upregulation, suppresses inflammatory cytokines including TGF-beta and TNF-alpha, and promotes angiogenesis by inducing VEGF and FGF-2 expression. Gene expression studies by Pickart et al. using the Broad Institute Connectivity Map showed GHK can influence the expression of over 4,000 genes, with patterns suggesting suppression of fibrosis-related and inflammation-related gene networks.

The Glow Blend combines three peptides with complementary tissue-repair and skin-remodeling mechanisms. GHK-Cu (copper tripeptide-1) is the primary cosmetic-active component, directly stimulating collagen and glycosaminoglycan synthesis in dermal fibroblasts while modulating matrix metalloproteinases for organized tissue remodeling. Its gene expression effects span over 4,000 genes related to tissue repair, antioxidant defense, and inflammation suppression.

BPC-157 adds a potent pro-angiogenic dimension to the blend. By upregulating VEGF and its receptors, BPC-157 promotes the formation of new blood vessels that are essential for delivering nutrients and oxygen to regenerating tissue. Its interaction with the nitric oxide system provides additional support for vascular function and tissue healing. BPC-157's broad cytoprotective properties complement GHK-Cu's remodeling activity.

TB-500 (thymosin beta-4 fragment) contributes through its unique mechanism of sequestering G-actin monomers and promoting actin polymerization, which is the driving force behind cell migration. In wound healing, cell migration is often the rate-limiting step — keratinocytes and fibroblasts must physically move into the wound bed before repair can occur. TB-500 facilitates this migration while also exhibiting anti-inflammatory effects through suppression of NF-kB-mediated cytokine release. The combination of these three peptides addresses wound healing at multiple levels: vascular supply (BPC-157), matrix remodeling (GHK-Cu), and cellular migration (TB-500).

GLP-3 RT-2 represents a next-generation approach to incretin receptor agonism. While classical GLP-1 receptor agonists (like semaglutide and liraglutide) target only the GLP-1 receptor, newer research has focused on multi-receptor agonists that simultaneously engage GLP-1, GIP, and glucagon receptors. This compound is designed to leverage the growing understanding that metabolic regulation involves complex interplay between multiple incretin and glucagon pathways.

The GLP-1 receptor axis, when activated, stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon release, slows gastric emptying, and promotes satiety through central nervous system pathways. GIP (glucose-dependent insulinotropic polypeptide) receptor activation enhances beta-cell function and, when combined with GLP-1 activity, produces greater metabolic effects than GLP-1 alone — as demonstrated by the success of tirzepatide (a dual GIP/GLP-1 agonist).

Research on this class of compounds is in relatively early stages. The rationale for multi-receptor targeting stems from clinical observations that dual and triple agonists produce superior metabolic outcomes compared to single-agonist approaches, as each receptor pathway contributes distinct physiological effects that are complementary rather than redundant.

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue that acts as a selective agonist of the ghrelin/growth hormone secretagogue receptor (GHS-R1a). Unlike earlier GHS compounds such as GHRP-6 and GHRP-2, ipamorelin is notable for its high selectivity — it stimulates growth hormone release without significantly affecting cortisol, prolactin, or ACTH levels at GH-stimulating doses. This selectivity was first characterized by Raun and colleagues at Novo Nordisk in 1998.

Ipamorelin binds GHS-R1a on pituitary somatotroph cells, triggering intracellular calcium influx via phospholipase C and IP3 pathways. This calcium mobilization causes GH-containing granule fusion with the cell membrane and GH exocytosis. The peptide produces dose-dependent GH release with a well-defined dose-response curve and a ceiling effect, meaning higher doses do not produce proportionally greater GH release — a property that contributes to its safety profile.

Research has also explored ipamorelin's effects on gastrointestinal motility. Hansen et al. demonstrated that ipamorelin accelerates gastric emptying and colonic transit time in post-operative ileus models, leading to investigation as a potential prokinetic agent. This GI activity is mediated through ghrelin receptor activation in the enteric nervous system.

The Klow Blend builds upon the Glow Blend formulation (GHK-Cu + BPC-157 + TB-500) with the addition of KPV, a C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (alpha-MSH). This four-peptide combination addresses tissue regeneration through complementary pathways with enhanced anti-inflammatory and antimicrobial capabilities.

KPV (Lys-Pro-Val) is the minimal active anti-inflammatory sequence derived from alpha-MSH. Unlike full-length alpha-MSH, KPV does not activate melanocortin receptors involved in pigmentation. Instead, it enters cells and directly inhibits NF-kB activation by preventing the phosphorylation of IkB-alpha and the nuclear translocation of NF-kB p65. This mechanism suppresses the production of a wide array of pro-inflammatory cytokines including IL-1beta, IL-6, IL-8, and TNF-alpha. Luger et al. demonstrated KPV also has direct antimicrobial activity against Staphylococcus aureus and Candida albicans.

The four-peptide combination creates a comprehensive tissue-repair system: GHK-Cu drives collagen synthesis and matrix remodeling; BPC-157 promotes angiogenesis through VEGF upregulation; TB-500 accelerates cell migration via actin regulation; and KPV provides potent anti-inflammatory activity through NF-kB suppression plus antimicrobial protection. The addition of KPV is particularly relevant in wound-healing contexts where infection and excessive inflammation are major impediments to repair.

Tesamorelin is a synthetic analogue of human GHRH (growth hormone-releasing hormone) comprising all 44 amino acids of native GHRH with an added trans-3-hexenoic acid moiety at the N-terminus. This modification enhances resistance to DPP-4 enzymatic degradation without altering receptor binding affinity, resulting in improved bioavailability compared to native GHRH. Tesamorelin is FDA-approved under the brand name Egrifta for the treatment of excess visceral abdominal fat in HIV-infected patients with lipodystrophy.

Tesamorelin binds to GHRH receptors on anterior pituitary somatotrophs, stimulating GH synthesis and secretion through the cAMP/PKA signaling cascade. Like sermorelin, it promotes physiological pulsatile GH release while preserving somatostatin-mediated feedback regulation. The resulting GH elevation stimulates hepatic IGF-1 production and downstream metabolic effects including lipolysis, particularly in visceral adipose depots.

Clinical trials demonstrated significant reductions in visceral adipose tissue (VAT) — approximately 15-18% reduction over 26 weeks in HIV lipodystrophy patients. Importantly, tesamorelin reduced VAT without significantly affecting subcutaneous fat, suggesting preferential action on metabolically active visceral depots. Additional research has explored cognitive benefits, with Stanley et al. demonstrating improved executive function and verbal memory in older adults.

Thymalin is a polypeptide preparation originally isolated from calf thymus glands, developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. It consists of a complex of small peptides that have been studied extensively in Russian clinical practice for immunomodulatory and geroprotective properties. The primary bioactive component is believed to be the dipeptide Glu-Trp, which has been studied independently as a thymic bioregulator.

The mechanism of action involves modulation of T-cell maturation and differentiation pathways. The thymus is the primary organ responsible for T-cell development and education, but it undergoes progressive involution (shrinkage) with age, leading to diminished output of naive T-cells and gradual immune decline (immunosenescence). Thymalin research focuses on its ability to partially restore thymic function and improve T-cell populations.

Khavinson et al. conducted a landmark 15-year longitudinal study in elderly patients (60-80 years) who received annual cycles of thymalin combined with epithalamin (the precursor of synthetic epitalon). The treated group showed significantly improved immune function, reduced incidence of acute respiratory infections, ischemic heart disease, hypertension, osteoporosis, and osteoarthritis, and remarkably, a 2-fold reduction in mortality rate compared to controls. While these results are striking, the study was conducted in Russia and may not have been subject to the same peer review standards as Western clinical trials.

Thymosin beta-4 (Tbeta4) is a 43-amino-acid peptide that is the most abundant member of the beta-thymosin family. Despite its name (a historical artifact from its original isolation from thymus tissue), Tbeta4 is expressed in virtually all nucleated cells and is one of the most abundant intracellular peptides, with concentrations reaching 0.4 mM in some cell types. TB-500 is a synthetic version commonly used in research.

The primary intracellular function of Tbeta4 is sequestration of G-actin (globular, monomeric actin), regulating the pool of actin available for polymerization into F-actin (filamentous actin). This function is critical because actin polymerization drives cell migration — a rate-limiting step in wound healing. By maintaining a reserve of polymerization-ready G-actin, Tbeta4 enables rapid cell migration when needed. The active site responsible for actin binding is the central region containing the sequence LKKTET.

Beyond actin regulation, Tbeta4 has potent anti-inflammatory activity. It suppresses NF-kB signaling and reduces pro-inflammatory cytokine expression. Bock-Marquette et al. made a landmark discovery showing Tbeta4 activates Akt (protein kinase B) in cardiomyocytes, promoting survival after ischemic injury. This finding opened research into cardiac repair applications. Tbeta4 also promotes angiogenesis, hair follicle stem cell migration, and has been shown to reduce corneal inflammation and scarring.

The Wolverine Blend combines the two most extensively studied tissue-repair peptides in complementary research: BPC-157 and TB-500 (thymosin beta-4). The blend name references the fictional character's regenerative abilities, reflecting the synergistic healing potential suggested by the combined research profiles of these peptides.

BPC-157 acts primarily through pro-angiogenic mechanisms — it upregulates VEGF, EGF, and their receptors to promote new blood vessel formation at injury sites. It also modulates the nitric oxide system and the FAK-paxillin pathway critical for cell adhesion and migration during wound repair. Its effects have been demonstrated across tendon, ligament, muscle, bone, skin, and gastrointestinal tissues in over 100 animal studies.

TB-500 acts through a complementary mechanism centered on actin biology. By sequestering G-actin monomers, TB-500 regulates the pool of actin available for polymerization, which directly controls cell migration speed. Since cell migration into wound beds is often the rate-limiting step in tissue repair, TB-500 effectively removes this bottleneck. It additionally provides anti-inflammatory activity through NF-kB suppression and promotes cardiomyocyte survival through Akt activation.

The rationale for combining these peptides is that they address different stages and requirements of the healing cascade: BPC-157 establishes the vascular supply needed for repair, while TB-500 accelerates the cellular migration that populates the repair site. Together, they create conditions for faster, more complete tissue regeneration than either alone.

GLP-2 TZ is a research analogue related to glucagon-like peptide-2 (GLP-2), a 33-amino-acid hormone co-secreted with GLP-1 from intestinal L-cells. While GLP-1 is well known for its metabolic effects, GLP-2 has a distinct physiological role: it is the primary endogenous intestinotrophic growth factor, meaning it specifically promotes growth and repair of the intestinal mucosa.

Native GLP-2 binds to GLP-2 receptors expressed on intestinal subepithelial myofibroblasts and enteric neurons. Receptor activation triggers downstream signaling through IGF-1, ErbB ligands, and KGF (keratinocyte growth factor) that promotes crypt cell proliferation, villus elongation, and increased mucosal surface area. This leads to enhanced nutrient absorption capacity. GLP-2 also reduces intestinal permeability, suppresses mucosal inflammatory responses, and inhibits gastric acid secretion and gastric emptying.

Teduglutide (Gattex/Revestive) is an FDA-approved DPP-4-resistant GLP-2 analogue with a single amino acid substitution (Ala for position 2 Ala to Gly) that extends the half-life from 7 minutes to approximately 2-3 hours. It is approved for short bowel syndrome (SBS) in adults and children. GLP-2 TZ builds on this pharmacological class for research applications.

CJC-1295 without DAC, also known as Modified GRF(1-29), is a synthetic analogue of the first 29 amino acids of growth hormone-releasing hormone (GHRH) with four amino acid substitutions designed to improve metabolic stability. The modifications (Ala at position 2 to D-Ala, Asn at position 8 to Gln, Ala at position 15 to Ala (retained), and Met at position 27 to Leu) confer resistance to DPP-4 and other proteolytic enzymes while preserving full GHRH receptor binding affinity.

The 'without DAC' designation distinguishes it from CJC-1295 with DAC (Drug Affinity Complex), which includes a maleimidopropionic acid linker that enables covalent binding to serum albumin. Without the DAC modification, this version has a shorter half-life of approximately 30 minutes, producing a more physiological acute GH pulse rather than the sustained GH elevation seen with the DAC version.

CJC-1295 without DAC binds GHRH receptors on pituitary somatotrophs and activates the Gs-cAMP-PKA pathway to stimulate GH release. Its shorter-acting nature produces GH pulses that more closely mimic natural secretion patterns, which some researchers prefer for maintaining physiological feedback regulation. It is frequently studied in combination with ghrelin receptor agonists like ipamorelin for synergistic GH release.

CJC-1295 with DAC is the albumin-conjugating version of CJC-1295, featuring a Drug Affinity Complex (DAC) — a reactive maleimidopropionic acid group that forms a covalent bond with serum albumin after subcutaneous injection. This albumin conjugation dramatically extends the circulating half-life from approximately 30 minutes (without DAC) to 6-8 days, enabling sustained elevation of GH and IGF-1 from a single administration.

Once bound to albumin, the CJC-1295-DAC conjugate circulates with the albumin protein, slowly releasing active peptide that continuously stimulates GHRH receptors on pituitary somatotrophs. This produces a pattern of sustained GH elevation rather than the acute pulsatile pattern seen with the non-DAC version. Teichman et al. demonstrated in a landmark clinical study that a single injection produced dose-dependent GH increases sustained for up to 6 days and IGF-1 elevation for 9-11 days.

The sustained-release pharmacokinetics of CJC-1295 DAC are advantageous for research protocols requiring consistent GH/IGF-1 elevation, but some researchers prefer the non-DAC version because it better preserves the natural pulsatile GH secretion pattern. The choice between versions depends on the specific research question being addressed.

NAD+ is a fundamental coenzyme in cellular energy metabolism, serving as the primary electron carrier in mitochondrial oxidative phosphorylation and as an essential substrate for sirtuins (SIRT1-7), PARPs, and CD38/CD157 enzymes. NAD+ levels decline significantly with age, impairing sirtuin-mediated gene regulation, mitochondrial function, and DNA repair capacity.

The 500mg product contains the same NAD+ compound as the 1000mg biofermented version at a lower quantity. See the NAD 1000mg entry for comprehensive research details on NAD+ biology, the role of NAD+ decline in aging, and the therapeutic potential of NAD+ restoration.

MOTS-c is a 16-amino-acid peptide encoded by the mitochondrial genome within the 12S rRNA gene. Discovered by Changhan David Lee and Pinchas Cohen at the University of Southern California in 2015, it was one of the first mitochondrial-derived peptides (MDPs) identified with significant metabolic regulatory activity. Its discovery challenged the longstanding view that the mitochondrial genome encodes only 13 proteins, 22 tRNAs, and 2 rRNAs.

MOTS-c's primary mechanism involves activation of the AMPK (AMP-activated protein kinase) pathway, the master cellular energy sensor. It inhibits the folate cycle and de novo purine biosynthesis, leading to accumulation of AICAR (an endogenous AMPK activator). This AMPK activation promotes glucose uptake, fatty acid oxidation, and mitochondrial biogenesis — effects that closely mimic the metabolic benefits of exercise. Lee et al. showed that MOTS-c treatment prevented age-dependent and high-fat-diet-induced insulin resistance in mice.

Remarkably, MOTS-c can translocate to the nucleus during metabolic stress, where it regulates nuclear gene expression through interaction with the antioxidant response element (ARE). This represents a novel form of mitochondrial-nuclear communication (retrograde signaling). MOTS-c levels decline with age in human plasma, and exercise has been shown to acutely increase circulating MOTS-c levels, linking it to the molecular mechanisms underlying exercise benefits.

Selank 11mg contains the same selank heptapeptide as the 10mg product — a synthetic derivative of tuftsin with anxiolytic, nootropic, and immunomodulatory properties. The mechanism involves GABA-A receptor modulation, enkephalin-degrading enzyme inhibition, and BDNF expression enhancement. See the Selank 10mg entry for comprehensive research details.

The 11mg vial provides slightly more material than the 10mg version, offering flexibility for research protocols that require marginally larger quantities per vial.

SLU-PP-332 is a small molecule agonist of estrogen-related receptors (ERRs), particularly ERRalpha and ERRgamma. Developed by researchers at the University of Florida led by Thomas Bhurrows, it was identified as a novel 'exercise mimetic' that activates transcriptional programs normally induced by physical exercise. ERRs are orphan nuclear receptors (no known endogenous ligand) that regulate genes involved in mitochondrial biogenesis, oxidative phosphorylation, fatty acid oxidation, and angiogenesis.

When activated by SLU-PP-332, ERRs promote transcription of genes encoding mitochondrial respiratory chain complexes, fatty acid oxidation enzymes, and vascular growth factors in skeletal muscle. This produces a phenotypic shift toward more oxidative (endurance-type) muscle fiber characteristics. In mouse studies, SLU-PP-332 treatment increased running endurance by approximately 70% without exercise training, and protected against high-fat-diet-induced obesity.

Research on SLU-PP-332 is still in early preclinical stages. It represents a new pharmacological approach to mimicking exercise benefits — distinct from AMPK activators (like AICAR) or PPARdelta agonists (like GW501516) — by targeting the ERR transcription factor family that sits atop the mitochondrial biogenesis gene network.

LL-37 is the only human cathelicidin antimicrobial peptide, derived from the C-terminal cleavage of the 18-kDa precursor protein hCAP18 by proteinase 3. It is a 37-amino-acid amphipathic alpha-helical peptide produced by neutrophils, macrophages, epithelial cells, and other cell types as part of the innate immune defense.

LL-37's antimicrobial mechanism involves direct membrane disruption of microbial cells. Its amphipathic structure — with a hydrophobic face and a cationic (positively charged) face — enables it to insert into negatively charged microbial membranes, causing pore formation and cell lysis. It is active against a broad spectrum of Gram-positive and Gram-negative bacteria, fungi, and enveloped viruses. Crucially, LL-37 also disrupts bacterial biofilms at sub-bactericidal concentrations, a property that distinguishes it from many conventional antibiotics.

Beyond direct antimicrobial activity, LL-37 serves as a potent immunomodulator. It recruits immune cells to infection sites by acting as a chemoattractant for neutrophils, monocytes, and T-cells via the formyl peptide receptor-like 1 (FPRL1). It promotes wound healing by stimulating angiogenesis and re-epithelialization. LL-37 also modulates Toll-like receptor signaling, enhancing the immune response to bacterial products while dampening potentially harmful excessive inflammatory responses.

SS-31 (elamipretide) is a synthetic cell-permeable tetrapeptide developed by Hazel Szeto at Weill Cornell Medical College. It is designed to target the inner mitochondrial membrane by selectively binding to cardiolipin, a unique phospholipid found almost exclusively in the inner mitochondrial membrane. Cardiolipin plays a critical structural role in organizing electron transport chain (ETC) complexes into supercomplexes (respirasomes) that enable efficient electron transfer.

By binding cardiolipin, SS-31 stabilizes the cristae structure and ETC supercomplex organization, improving the efficiency of oxidative phosphorylation. This reduces electron leak and consequently decreases mitochondrial reactive oxygen species (ROS) production. Importantly, SS-31 does not act as a conventional antioxidant that scavenges ROS after they are produced — instead, it prevents excess ROS generation at the source by optimizing ETC function.

SS-31 has shown therapeutic potential across multiple organ systems in preclinical and clinical studies. It reduces infarct size in cardiac ischemia-reperfusion injury, protects renal tubular cells from ischemic damage, improves skeletal muscle function in aged animals, and reverses age-related mitochondrial dysfunction. It has advanced to Phase II/III clinical trials for heart failure (Barth syndrome, primary mitochondrial myopathy, and heart failure with preserved ejection fraction).

5-Amino-1MQ is a small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), a cytoplasmic enzyme that methylates nicotinamide (a form of vitamin B3) using S-adenosylmethionine (SAM) as a methyl donor. NNMT is highly expressed in adipose tissue and liver, and its activity increases with obesity. By consuming nicotinamide, NNMT reduces the availability of substrate for NAD+ biosynthesis through the salvage pathway.

Inhibiting NNMT with 5-Amino-1MQ has two beneficial metabolic consequences. First, it increases the pool of nicotinamide available for NAD+ synthesis, thereby boosting cellular NAD+ levels. Since NAD+ is essential for sirtuin activity and mitochondrial function, this effectively enhances metabolic efficiency. Second, NNMT inhibition reduces the consumption of SAM, increasing the SAM/SAH (S-adenosylhomocysteine) ratio, which influences cellular methylation reactions broadly.

Naughton et al. at the University of Texas demonstrated that NNMT inhibition with 5-Amino-1MQ reduced adiposity in diet-induced obese mice without affecting food intake, suggesting direct metabolic effects on fat tissue rather than appetite suppression. The compound also reduced adipocyte size, decreased lipid accumulation, and increased energy expenditure, consistent with the expected effects of enhanced NAD+ availability and improved metabolic efficiency.

Vitamin B12 (cobalamin) is an essential water-soluble vitamin that functions as a coenzyme in two critical enzymatic reactions in human metabolism. First, as methylcobalamin, it serves as a cofactor for methionine synthase, which converts homocysteine to methionine — a reaction critical for DNA methylation, neurotransmitter synthesis, and prevention of homocysteine accumulation. Second, as adenosylcobalamin, it serves as a cofactor for methylmalonyl-CoA mutase, which converts methylmalonyl-CoA to succinyl-CoA in the propionate catabolism pathway, feeding into the citric acid cycle.

B12 deficiency impairs both reactions, leading to megaloblastic anemia (from disrupted DNA synthesis in rapidly dividing hematopoietic cells), neurological damage (from impaired myelin synthesis and possible methylation defects), and elevated homocysteine (a cardiovascular risk factor). The neurological manifestations can include peripheral neuropathy, subacute combined degeneration of the spinal cord, cognitive decline, and depression.

The 10ml solution format allows for direct use without reconstitution. B12 is often included alongside peptide research protocols because many peptide-active metabolic pathways depend on adequate methylation status and mitochondrial function, both of which require B12.

KPV is the C-terminal tripeptide (amino acids 11-13) of alpha-melanocyte-stimulating hormone (alpha-MSH). Despite being the smallest anti-inflammatory fragment of alpha-MSH, KPV retains potent anti-inflammatory activity through a unique mechanism that does not require melanocortin receptor binding. This distinguishes it from full-length alpha-MSH and melanotan peptides, which act through MC1R-MC5R receptors.

KPV enters cells and directly inhibits NF-kB activation by preventing the phosphorylation of IkB-alpha and the subsequent nuclear translocation of the NF-kB p65 subunit. By blocking this master inflammatory transcription factor, KPV suppresses the production of a broad array of pro-inflammatory mediators including TNF-alpha, IL-1beta, IL-6, IL-8, and nitric oxide. Brzoska et al. demonstrated this intracellular mechanism is independent of cell-surface melanocortin receptor engagement.

KPV also exhibits direct antimicrobial activity against several pathogens including Staphylococcus aureus and Candida albicans. In gastrointestinal research, Kannengiesser et al. showed KPV reduces colonic inflammation in murine colitis models, protecting mucosal integrity and reducing tissue damage. This dual anti-inflammatory and antimicrobial profile makes KPV relevant to IBD research and wound healing applications where infection and inflammation coexist.

Kisspeptin is a neuropeptide product of the KISS1 gene that serves as a critical regulator of the hypothalamic-pituitary-gonadal (HPG) axis. It was discovered in 2003 by two independent groups (de Roux et al. and Seminara et al.) who identified loss-of-function mutations in the kisspeptin receptor (GPR54/KISS1R) as a cause of hypogonadotropic hypogonadism — failure to undergo puberty due to absent GnRH signaling.

Kisspeptin is the most potent known stimulator of gonadotropin-releasing hormone (GnRH) secretion. Kisspeptin neurons in the hypothalamic arcuate nucleus and anteroventral periventricular nucleus express KISS1R and project directly to GnRH neurons. Upon kisspeptin binding, KISS1R activation stimulates GnRH neurons to release GnRH into the portal circulation, which in turn triggers LH and FSH release from the anterior pituitary.

Kisspeptin-10 is the minimal bioactive C-terminal fragment (amino acids 45-54 of the full 54-amino-acid kisspeptin-54) that retains full KISS1R binding and activation. Research has explored kisspeptin as a diagnostic tool for reproductive disorders and as a potential therapeutic for infertility. Dhillo et al. demonstrated that kisspeptin-54 infusion potently stimulates LH secretion in healthy men and women, and subsequent work has explored its use in triggering oocyte maturation for IVF without the risk of ovarian hyperstimulation syndrome.

Glutathione (GSH) is a tripeptide (gamma-glutamylcysteinylglycine) that serves as the body's most abundant intracellular antioxidant. It is present in millimolar concentrations in virtually all mammalian cells, with particularly high levels in the liver, where it plays a central role in detoxification and xenobiotic metabolism.

GSH functions as the primary substrate for glutathione peroxidase (GPx), which neutralizes hydrogen peroxide and lipid hydroperoxides. In this reaction, reduced GSH is oxidized to GSSG (glutathione disulfide), which is then regenerated by glutathione reductase using NADPH. The GSH/GSSG ratio is a key indicator of cellular redox status — a declining ratio indicates oxidative stress.

Beyond direct antioxidant activity, GSH is essential for Phase II hepatic detoxification via glutathione S-transferases (GSTs), which conjugate glutathione to electrophilic xenobiotics, drugs, and carcinogens for elimination. GSH also supports immune function — lymphocyte proliferation and natural killer cell activity depend on adequate GSH levels. Wu et al. demonstrated that GSH depletion impairs T-cell function, while supplementation restores immune responses. Glutathione levels decline with age, chronic disease, and environmental toxin exposure, making GSH status a biomarker of overall health.

Bacteriostatic water for injection is sterile water that contains 0.9% benzyl alcohol as a preservative. The benzyl alcohol inhibits microbial growth, allowing the solution to be used for multiple reconstitutions over a period of time — unlike sterile water for injection, which must be used immediately after opening and cannot be stored.

The benzyl alcohol preservative works by disrupting bacterial cell membranes through its amphipathic structure, which inserts into and disorganizes the lipid bilayer. At the 0.9% concentration used in bacteriostatic water, it is bacteriostatic (inhibits growth) rather than bactericidal (kills). This level is sufficient to prevent microbial contamination during the multi-use period while being well-tolerated in research applications.

Bacteriostatic water is the standard diluent for reconstituting lyophilized peptides in research settings. When added to lyophilized peptide vials, it dissolves the peptide while the benzyl alcohol preservative maintains sterility for the use period. The water is isotonic-compatible and has a neutral pH, making it suitable for peptide reconstitution without affecting peptide stability or activity.

Semax is a synthetic heptapeptide based on ACTH(4-7) (the fragment Met-Glu-His-Phe from adrenocorticotropic hormone) with an added Pro-Gly-Pro C-terminal extension for metabolic stability. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences alongside selank, semax is approved in Russia as a nootropic and neuroprotective medication.

Semax does not activate the melanocortin receptors associated with full-length ACTH and does not affect cortisol or adrenal function. Instead, it influences brain function through modulation of neurotrophic factor expression. Research has shown semax significantly upregulates BDNF (brain-derived neurotrophic factor) and its receptor TrkB, as well as NGF (nerve growth factor) in the hippocampus and cortex. These neurotrophins are critical for neuronal survival, synaptic plasticity, and learning.

Semax also modulates monoaminergic neurotransmission. It influences dopaminergic and serotonergic systems in the brain, which may contribute to its cognitive-enhancing and antidepressant-like effects observed in behavioral studies. In stroke research, semax has shown neuroprotective effects when administered during the acute phase of cerebral ischemia, reducing infarct volume and improving functional outcomes in animal models.